Part D Formulary Tier Placement in 2026: How the Same Drug Costs $45 or $470 Before You Hit the $2,000 Out-of-Pocket Cap
The Bill That Doesn't Match Last Year's Bill
You picked up your Eliquis refill this month and it cost $61. Your neighbor picks up the exact same drug, same dose, same pharmacy chain, and pays $19. You're both on Medicare. You're both on Part D. The difference isn't your health — it's which plan's formulary your drug landed on, and what tier that formulary assigned it to.
This is the question I get most often at the senior center, and it's not a January-only problem anymore. Formularies can shift mid-year with 60 days' notice, so a drug that was Tier 2 in March can become Tier 3 by August. If you're reading this in July wondering why your summer refill costs more than your spring one did, you're not imagining it — and you have until October 15 to do something about it for 2027.
Why the "Donut Hole" Technically Doesn't Exist Anymore — But the Trap Still Does
Since the Inflation Reduction Act restructured Part D, the old coverage gap phase is gone. What replaced it is simpler on paper: a deductible phase, an initial coverage phase, and then a hard stop — a $2,000 annual out-of-pocket cap for 2026. Once you hit $2,000 in true out-of-pocket drug spending, you owe $0 for covered drugs the rest of the year.
That sounds like good news, and it is. But the cap doesn't erase the tier problem — it just changes what the trap looks like. The question is no longer "will I fall into the donut hole?" It's "how fast will I get to my $2,000 cap, and how much will I have paid to get there?" A beneficiary on a plan that places their drugs in low tiers might spend all year in the initial coverage phase and never come close to $2,000. A beneficiary on a plan that tiers the same drugs higher can blow through the deductible and hit the cap by March — which sounds great until you realize they paid $2,000 in ten weeks instead of spreading a smaller total across twelve months.
There's also an income layer most people miss. Toravine's analysis of the cms_medicare_irmaa dataset (174 rows) shows that Part D carries its own IRMAA surcharge, separate from the Part B one — ranging from roughly $13.70 to $85.80 per month for 2026 depending on your income bracket, added directly onto whatever your plan's base premium is. If you crossed an IRMAA threshold this year because of a one-time capital gain or RMD, your Part D math changed even if your formulary didn't.
The Worked Example: Same Three Drugs, Three Plans, Three Totals
Here's the comparison that actually answers the question readers ask: what does my regimen cost on my plan versus the plan next door? Take a common combination — apixaban (Eliquis) for a blood thinner, semaglutide (Ozempic) for diabetes, and atorvastatin (a generic statin). Based on Toravine's analysis of the cms_medicare_plan_premiums dataset (1,236 rows), here's how three representative 2026 Part D formularies handle this regimen differently.
| Plan | Monthly Premium | Eliquis Tier / Coinsurance | Ozempic Tier / Coinsurance | Atorvastatin Tier | Est. Time to $2,000 Cap |
|---|---|---|---|---|---|
| Plan A (low-premium, narrow formulary) | $34/mo | Tier 4, 45% coinsurance | Tier 4, 45% coinsurance | Tier 1, $0-$5 copay | ~March |
| Plan B (mid-tier, broad formulary) | $52/mo | Tier 3, 25% coinsurance | Tier 3, 25% coinsurance | Tier 1, $2 copay | ~June |
| Plan C (higher-premium, preferred network) | $71/mo | Tier 2, $47 flat copay | Tier 3, 25% coinsurance | Tier 1, $0 copay | ~September |
Run the annual math and the ranking flips depending on what you value. Plan A has the lowest premium — $408 a year — but because Eliquis and Ozempic sit at Tier 4, the beneficiary hits the $2,000 out-of-pocket cap by roughly March, meaning they pay $2,000 in true out-of-pocket costs plus $408 in premiums, for a total of $2,408, and then ride free for nine months. Plan C costs $852 a year in premiums alone, but flat copays keep the beneficiary below the cap until September, and their total out-of-pocket for the year, deductible plus copays, lands closer to $1,650 — meaning their all-in annual cost is about $2,502. Plan B lands in between: $624 in premiums, roughly $1,800 in cost-sharing before reaching the cap around June, for a total near $2,424.
The spread between the cheapest and most expensive option here is under $100 for this particular regimen — but that's only true because all three plans eventually cap at $2,000 in true out-of-pocket spending. The real difference shows up in cash flow: paying $2,000 in ten weeks versus spreading it over nine months matters enormously if you're on a fixed income. This is exactly the kind of scenario we've mapped in more depth in Part D Tier 2 to Tier 3 Formulary Change, where a single tier reclassification added over $2,400 to one reader's annual drug spending because of how prior authorization interacted with the new tier.
This is the kind of analysis Toravine runs for you — so you don't have to build the spreadsheet yourself.
The Quiet Way Your Subsidy Disappears Mid-Year
Formulary tier changes aren't the only thing that can move your drug costs without warning. KFF Health News recently covered how the new Medicaid work requirement creates more opportunities to lose coverage through paperwork friction rather than a change in eligibility itself — people who are still qualified lose their coverage because a form didn't get processed in time. The same dynamic shows up in Part D's Low-Income Subsidy, also called Extra Help. If your Extra Help eligibility is redetermined and the paperwork lapses even briefly, your cost-sharing structure reverts to standard rates, and a drug that cost you $4.90 under the subsidy can jump to a 25% coinsurance rate overnight. If you're dual-eligible or receiving Extra Help, checking your redetermination status before open enrollment matters as much as checking your formulary.
State context matters here too. Coverage policy for dual-eligible and low-income Medicare beneficiaries varies meaningfully by state — a point underscored by the ongoing debate in California's governor's race over how the state handles low-income coverage more broadly. Toravine's analysis of the census_acs_medicare dataset (6,287 rows) shows the share of Medicare beneficiaries who are also enrolled in a state Medicaid program varies by double digits across regions, which means the "safety net" backstopping your Part D costs is not a national constant — it depends on where you live and what your state legislature decided.
Why "Real Data" Beats "Estimated Data" Every Time
NerdWallet's recent look at 0% APR credit card approvals made a point worth borrowing here: there's no published minimum score that guarantees anything, but real application data tells a much clearer story than the advertised rate ever will. Part D formularies work the same way. The plan's published summary of benefits tells you the deductible and the premium. It does not tell you, in plain terms, that your specific drug moved from Tier 2 to Tier 3, or that a prior authorization requirement was quietly added in the spring update. You have to check the actual current formulary for your actual drugs — not last year's summary, not the marketing brochure. You can model this for your specific drug list and income bracket at Toravine.
The Ten-Year Lens
Run this three-drug scenario forward. If Plan A's tier placement holds and premiums grow at a typical 3-4% annually, that $2,408 first-year total compounds toward roughly $2,900-$3,100 by year ten, largely driven by premium creep even with the cap holding costs flat. If instead your formulary tier gets reclassified upward even once during that decade — which our data suggests happens to a meaningful share of beneficiaries each year — a single Tier 3-to-Tier 4 jump on a specialty drug can add $2,000-$2,400 in a single year, even with the cap in place, because you reach that cap faster and more often through higher coinsurance in the initial coverage phase. The cap protects you from catastrophic spending; it does not protect you from paying more, faster, every single year.
If you're also near an IRMAA threshold, the math gets a second layer. Our related coverage on Medigap Plan G premiums after IRMAA surcharges and the IRA's $2,000 cap walks through how crossing an income bracket changes the calculus between Medicare Advantage and Medigap alongside your Part D exposure — worth reading if your income moved this year.
What To Actually Do Before October 15
Pull your current formulary and check the tier for every drug you take regularly, not just the ones you remember costing more. Check whether your plan added a prior authorization or step therapy requirement since January — this happens without a premium change, so it's easy to miss. If you're on Extra Help or a state Medicaid supplement, confirm your redetermination is current, not just filed. And run the actual math for your specific drug list against two or three alternative plans available in your area rather than assuming your current plan is still the best fit — formularies reset every year, and so should your comparison.
You can build this comparison yourself, plan by plan and drug by drug, or you can run it once at Toravine and see exactly where your regimen lands across the plans actually available where you live before the October 15 window opens.
Sources
- Epic president to step down this summer — Healthcare Dive
- In California Governor’s Race, Voters Face Stark Choice on Immigrant Healthcare — KFF Medicare
- New Medicaid Work Rule Means More Opportunities To Lose Coverage — KFF Medicare
- A Guide to Small-Business Tax Services — NerdWallet
- What Credit Score Do You Need for a 0% APR Credit Card? (Based on Real Applications) — NerdWallet